Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy MacroGenics (MGNX) stock
Learn how to easily invest in MacroGenics stock.
MacroGenics, Inc is a biotechnology business based in the US. MacroGenics shares (MGNX) are listed on the NASDAQ and all prices are listed in US Dollars. MacroGenics employs 370 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in MacroGenics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – MGNX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
MacroGenics stock price (NASDAQ: MGNX)Use our graph to track the performance of MGNX stocks over time.
MacroGenics shares at a glance
|Latest market close||$32.19|
|52-week range||$18.16 - $36.48|
|50-day moving average||$24.95|
|200-day moving average||$26.78|
|Wall St. target price||$36.78|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.47|
Buy MacroGenics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy MacroGenics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
MacroGenics price performance over time
|1 week (2021-07-17)||N/A|
|1 month (2021-06-28)||22.49%|
|3 months (2021-04-28)||-8.78%|
|6 months (2021-01-24)||N/A|
|1 year (2020-07-24)||N/A|
|2 years (2019-07-24)||N/A|
|3 years (2018-07-24)||N/A|
|5 years (2016-07-24)||N/A|
Is MacroGenics under- or over-valued?
Valuing MacroGenics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MacroGenics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
MacroGenics's PEG ratio
MacroGenics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.01. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into MacroGenics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$108.1 million|
|Gross profit TTM||$-88,318,000|
|Return on assets TTM||-24.42%|
|Return on equity TTM||-50.37%|
|Market capitalisation||$1.5 billion|
TTM: trailing 12 months
Shorting MacroGenics shares
There are currently 4.3 million MacroGenics shares held short by investors – that's known as MacroGenics's "short interest". This figure is 4.5% up from 4.1 million last month.
There are a few different ways that this level of interest in shorting MacroGenics shares can be evaluated.
MacroGenics's "short interest ratio" (SIR)
MacroGenics's "short interest ratio" (SIR) is the quantity of MacroGenics shares currently shorted divided by the average quantity of MacroGenics shares traded daily (recently around 1.2 million). MacroGenics's SIR currently stands at 3.56. In other words for every 100,000 MacroGenics shares traded daily on the market, roughly 3560 shares are currently held short.
However MacroGenics's short interest can also be evaluated against the total number of MacroGenics shares, or, against the total number of tradable MacroGenics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MacroGenics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 MacroGenics shares in existence, roughly 70 shares are currently held short) or 0.0797% of the tradable shares (for every 100,000 tradable MacroGenics shares, roughly 80 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against MacroGenics.
Find out more about how you can short MacroGenics stock.
MacroGenics share dividends
We're not expecting MacroGenics to pay a dividend over the next 12 months.
MacroGenics share price volatility
Over the last 12 months, MacroGenics's shares have ranged in value from as little as $18.16 up to $36.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MacroGenics's is 2.2454. This would suggest that MacroGenics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
MacroGenics, Inc. , a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications.
Stocks similar to MacroGenics
MacroGenics in the news
MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call
MacroGenics (MGNX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call
Frequently asked questionsWhat percentage of MacroGenics is owned by insiders or institutions?
Currently 2.609% of MacroGenics shares are held by insiders and 98.483% by institutions. How many people work for MacroGenics?
Latest data suggests 370 work at MacroGenics. When does the fiscal year end for MacroGenics?
MacroGenics's fiscal year ends in December. Where is MacroGenics based?
MacroGenics's address is: 9704 Medical Center Drive, Rockville, MD, United States, 20850 What is MacroGenics's ISIN number?
MacroGenics's international securities identification number is: US5560991094 What is MacroGenics's CUSIP number?
MacroGenics's Committee on Uniform Securities Identification Procedures number is: 556099109
More guides on Finder
How to buy Clover Finance (CLV) in the US
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
How to buy AT-and-T (T) stock
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
How to buy HNC Coin (HNC) in the US
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
How to buy Maro (MARO) in the US
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
How to buy Ethernity Chain (ERN) in the US
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
How to buy Shopping.io (SPI) in the US
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
How to buy LUKSO Token (LYXE) in the US
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
How to buy KardiaChain (KAI) in the US
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
How to buy Neutrino USD (USDN) in the US
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
How to buy Venus BTC (VBTC) in the US
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
Ask an Expert